Cadrenal Therapeutics, Inc. Common Stock (CVKD) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Cadrenal Therapeutics, Inc. Common Stock (CVKD) has a cash flow conversion efficiency ratio of -1.671x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-3.00 Million) by net assets ($1.80 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See CVKD defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Cadrenal Therapeutics, Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2022–2025)
This chart illustrates how Cadrenal Therapeutics, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Cadrenal Therapeutics, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Cadrenal Therapeutics, Inc. Common Stock ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
SCANDIN.ENVIRO SYSTEMS AB
F:1HR
|
-0.116x |
|
Flour Mills Kepenos S.A.
AT:KEPEN
|
0.322x |
|
Steel City Securities Limited
NSE:STEELCITY
|
0.025x |
|
Thunderful Group AB
ST:THUNDR
|
-0.023x |
|
Inocycle Technology Tbk PT
JK:INOV
|
0.029x |
|
Ganges Securities Limited
NSE:GANGESSECU
|
0.029x |
|
Cyclerion Therapeutics Inc
NASDAQ:CYCN
|
-0.173x |
|
Seremban Engineering Bhd
KLSE:5163
|
0.344x |
Annual Cash Flow Conversion Efficiency for Cadrenal Therapeutics, Inc. Common Stock (2022–2025)
The table below shows the annual cash flow conversion efficiency of Cadrenal Therapeutics, Inc. Common Stock from 2022 to 2025. For the full company profile with market capitalisation and key ratios, see CVKD market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $2.74 Million | $-12.60 Million | -4.601x | -365.26% |
| 2024-12-31 | $7.44 Million | $-7.36 Million | -0.989x | -115.49% |
| 2023-12-31 | $7.69 Million | $-3.53 Million | -0.459x | -311.46% |
| 2022-12-31 | $-5.55 Million | $-1.20 Million | 0.217x | -- |
About Cadrenal Therapeutics, Inc. Common Stock
Cadrenal Therapeutics, Inc. operates as a late-stage biopharmaceutical company focuses on developing therapeutics for rare cardiovascular conditions. The company is developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with… Read more